Tuftsin Promotes an Anti-Inflammatory Switch and Attenuates Symptoms in Experimental Autoimmune Encephalomyelitis by Wu, Muzhou et al.
Tuftsin Promotes an Anti-Inflammatory Switch and
Attenuates Symptoms in Experimental Autoimmune
Encephalomyelitis
Muzhou Wu
1,2, Jillian C. Nissen
1,3, Emily I. Chen
1,4, Stella E. Tsirka
1,2,3*
1Department of Pharmacological Sciences, School of Medicine, Stony Brook University, Stony Brook, New York, United States of America, 2Program in Neuroscience,
School of Medicine, Stony Brook University, Stony Brook, New York, United States of America, 3Program in Molecular and Cellular Pharmacology, School of Medicine,
Stony Brook University, Stony Brook, New York, United States of America, 4Stony Brook University Proteomics Center, School of Medicine, Stony Brook University, Stony
Brook, New York, United States of America
Abstract
Multiple sclerosis (MS) is a demyelinating autoimmune disease mediated by infiltration of T cells into the central nervous
system after compromise of the blood-brain barrier. We have previously shown that administration of tuftsin, a
macrophage/microglial activator, dramatically improves the clinical course of experimental autoimmune encephalomyelitis
(EAE), a well-established animal model for MS. Tuftsin administration correlates with upregulation of the immunosuppres-
sive Helper-2 Tcell (Th2) cytokine transcription factor GATA-3. We now show that tuftsin-mediated microglial activation
results in shifting microglia to an anti-inflammatory phenotype. Moreover, the T cell phenotype is shifted towards
immunoprotection after exposure to tuftsin-treated activated microglia; specifically, downregulation of pro-inflammatory
Th1 responses is triggered in conjunction with upregulation of Th2-specific responses and expansion of immunosuppressive
regulatory T cells (Tregs). Finally, tuftsin-shifted T cells, delivered into animals via adoptive transfer, reverse the pathology
observed in mice with established EAE. Taken together, our findings demonstrate that tuftsin decreases the
proinflammatory environment of EAE and may represent a therapeutic opportunity for treatment of MS.
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Introduction
Multiple sclerosis (MS) is a chronic debilitating autoimmune
disease in which T cells, microglia and macrophages aberrantly
attack the myelin sheath that protects nerve fibers in the brain and
spinal cord. The symptoms of MS vary from sensory defects, such
as blurry vision, to loss of balance, muscle weakness, and paralysis
[1]. Experimental autoimmune encephalomyelitis (EAE) is an
induced autoimmune disease used as one of the animal models to
study MS. During EAE, activated T cells, which are normally
absent from the central nervous system (CNS), infiltrate the CNS
through the compromised blood-brain barrier (BBB). The
activated T cells initiate an inflammatory cascade that generates
cytokines and chemokines, and attack the myelinated neurons
causing demyelination in the CNS. Resident microglia also
undergo activation and trigger the recruitment of peripheral
macrophages, which release cytokines and chemokines that
propagate disease progression [2–5] and subsequent recovery.
Microglia are the immune-competent cells that reside in the
CNS. During MS and EAE, they become activated and contribute
to the inflammatory process through several mechanisms,
including phagocytosis and production of various factors such as
cytokines, free radicals, and metalloproteinases [6]. However, the
effects of microglia are not solely deleterious; microglia also
produce anti-inflammatory cytokines, such as TGFb and IL10 [7],
which are associated with inhibition or prevention of EAE. The
timing and strength of these protective and neurotoxic outputs
determine which overall effect predominates.
T cells undertake the primary role in modulating the outcome of
MS/EAE. Naı ¨ve T cells can differentiate into helper (Th) and
regulatory cells (Tregs). There are three subsets of T helper cells:
Th1, Th2 [8] and the more recently described Th17 cells [9]. Th1
cells produce proinflammatory cytokines (e.g. TNFalpha) and
mediate proinflammatory responses during MS/EAE, whereas
Th2 cells secrete anti-inflammatory cytokines [e.g. interleukin-4
(IL4), -10 (IL10), and -13 (IL13)] and participate in prevention or
remission of MS/EAE. Th17 cells produce interleukin-17 (IL17)
and play a pathogenic role in inducing autoimmune tissue
inflammation [10–12]. In the presence of TGFb, naive T cells
become Tregs, which express FOXP3 and suppress immune
system activation [11,13–16].
Tuftsin is a naturally occurring tetrapeptide (threonine-lysine-
proline-arginine) that was described originally as a phagocytosis-
stimulating factor derived from the proteolytic processing of IgG
[17]. Tuftsin promotes phagocytic activity for cells of monocytic
origin, such as neutrophils, macrophages and microglia, all of
which are thought to express tuftsin receptors. Tuftsin or tuftsin-
like peptides also exert other stimulatory effects, including
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can affect T-cell function as well [18]. Moreover, tuftsin may have
direct effects on the nervous system, including induction of
analgesia [19] and inhibition of axonal regeneration [20].
Previous work in our laboratory revealed that modification of
the status of microglia affected the timing and symptoms of EAE
[21]. In particular, the microglial activator tuftsin, which readily
crosses into the CNS [22], decreased the severity of EAE
symptoms and drastically improved recovery in wild-type mice.
Real-time PCR data revealed that wild-type EAE mice exhibited
prevalent T-bet expression, which is a transcription factor that
promotes Th1 lineage development and cytokine production.
Conversely, tuftsin infusion into wild-type mice subjected to EAE
resulted in increased GATA3 expression, which is a transcription
factor that drives Th2 lineage development and release of anti-
inflammatory cytokines. In this study, we used both in culture and in
vivo methods to investigate the mechanism through which tuftsin
modulates the immune response in EAE. Our results show that in
culture, modulating microglial activity with tuftsin affects T cell fate
by downregulating the Th1-proinflammatory responses and
upregulating anti-inflammatory cytokines. In vivo, tuftsin infusion
promotes dominance of a Th2 phenotype with increases in anti-
inflammatory cytokines and the emergence of markers character-
istic of immunosuppressive Tregs. Finally, adoptive transfer of
tuftsin-modulated T cells reverses clinical signs of disease in mice
with established EAE, which suggests promising therapeutic
opportunities.
Materials and Methods
Animals
C57BL/6 mice were bred in-house under specific pathogen-free
conditions [Division of Laboratory Animal Resources at the State
University of New York (SUNY) Stony Brook], controlled for
temperature (21uC), and maintained under a 12-hour light/dark
cycle. Access to food and water was ad libitum. Adult (6- to 8-
week-old) female mice were used in all experiments.
MOG peptide
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was
synthesized by Quality Controlled Biochemicals and purified using
reverse-phase (C18) HPLC.
Induction of EAE with MOG35–55 peptide
EAE was induced as described previously [21,23,24] by
subcutaneous injection into the mouse flank on day 0 with
300 mg of MOG35–55 peptide thoroughly emulsified in complete
Freund’s adjuvant (CFA) containing 500 mg of heat-inactivated
Mycobacterium tuberculosis (Difco, Detroit, MI). One week later
(day 7), the mice were boosted with 300 mg of MOG35–55 peptide
subcutaneously in the other flank. 500 ng Pertussis toxin (List
Biologicals, Campbell, CA) in 200 ml of PBS was injected
intraperitoneally on days 0 and 2.
Evaluation of EAE symptoms
After immunization with MOG, mice were observed and
weighed daily blindly. Symptom severity was scored on a scale of 0
to 5 with graduations of 0.5 for intermediate symptoms. The score
is defined as follows [25]: 0, no detectable symptoms; 1, loss of tail
tone; 2, hindlimb weakness or abnormal gait; 3, complete paralysis
of the hindlimbs; 4, complete hindlimb paralysis with forelimb
weakness or paralysis; 5, moribund or death.
Time-controlled Drug Delivery
Alzet mini-osmotic pumps (Durect, Cupertino, CA) were used
to ensure time-controlled drug delivery. 14-day pumps (rate of
infusion 0.25 ml/hr, 100 ml total volume) are filled with either PBS
or 500 mM tuftsin (American Peptide Company, Sunnyvale, CA)
and incubated at 37uC overnight before using. Adult female
C57Bl6 mice (6–10 weeks old) were deeply anesthetized, and
pumps were implanted subcutaneously in the back of the mice for
on day 1 after MOG immunization. Pumps were replaced with
fresh 14-day pumps on day 15 and maintained for the duration of
the experiment.
Eriochrome Cyanine stain and myelin quantification
Eriochrome cyanine (EC) staining was used to visualize myelin
in the lumbar region of the spinal cord, as we have previously
described [26]. In brief, spinal cord sections previously stored at
280uC were air-dried for 1 hour at room temperature and a
second hour at 37uC in a dry incubator. After incubation with
acetone for 5 minutes, the slides were air-dried for 30 minutes and
then stained in EC solution (0.2% eriochrome cyanine RS (Sigma),
0.5% H2SO4 (Sigma), 10% iron alum (Sigma) in distilled water for
30 minutes, differentiated in 5% iron alum (Sigma) for 10 min-
utes, and placed in borax-ferricyanide solution (1% borax (Sigma),
1.25% potassium ferricyanide (Sigma), in distilled water) for
5 minutes. The slides were then dehydrated through graded
ethanol solutions and coverslipped using Permount (Fisher
Scientific, NJ, USA). These were then visualized on a Nikon
Eclipse E600 microscope. Multiple images of several sections from
the same animal of the ventral white matter taken at 406
magnification were quantified for their demyelinated (unstained)
area using ImageJ software. When fluoromyelin was used the
quantification derived from sections from the lumbar spinal cord
using ImageJ. All white matter area was selected and average
intensity (total intensity/area) was generated as (Ave Iwhitematter);
then all grey matter area was selected (as background), the average
intensity (total intensity/area) was generated as (Ave Igreymatter).
Then the final value was (Ave Iwhitematter)2(Ave Igreymatter). The 3
different timepoints were chosen because they represent three
different stages during disease development and immune cell
response: early stage, peak and recovery.
Immunofluorescence
Mice were transcardiacally perfused using 4% paraformalde-
hyde/PBS and the spinal cords removed and post-fixed in 4%
paraformaldehyde/PBS for 1 hour at room temperature followed
by 30% sucrose dehydration at 4uC overnight. The spinal cords
were embedded in Tissue-Tek (Miles, Elkhart, IN) optimal cutting
temperature compound, frozen on dry ice, and stored at {80uC
until use. Cross sections (20 mm) were cut on a cryostat (Leica,
Nussloch, Germany) at {20uC.
Spinal cord sections were blocked in serum of the host of the
secondary antibody [5% serum in PBS-T (0.5% TritonX-100 in
PBS)], and then incubated overnight at 4uC in rabbit anti-mouse
Iba1 (Wako, Japan) at a 1:500 dilution in PBS to detect both
resting and activated microglia/macrophages. After washing in
PBS, sections were incubated with fluorescence-conjugated (FITC
or Texas Red) goat anti-rabbit secondary antibody for 1 hour at
room temperature, washed 3 times 10 minutes each with PBS, and
mounted using Fluoromount-G (Southern Biotech, USA).
Primary T cells culture from mouse spleen
The T cell negative isolation kit (Invitrogen) was used to retrieve
primary T cells from mouse spleens. Briefly, a mixture of
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monocytes, dendritic cells, CD8
+ T cells, erythrocytes and
granulocytes) was added to spleen cells. T cells were isolated by
removing the antibody-labeled cells using mouse depletion
Dynabeads and a Dynal MPC. The CD4
+ T cells were stimulated
with plate-bound anti-CD3 (10 mg/ml, BD Biosciences) antibody,
serving as ‘artificial APCs’ [27]. Cells were washed and
restimulated with anti-CD3 (5 mg/ml) before cytokine analysis,
as in [28].
Measurement of cytokine production
Purified T cells (2.5610
5 cells well) were stimulated with 0.1–
100 mg/ml MOG35–55 and/or 0.1–1 mg/ml plate-bound anti-
CD3/soluble anti-CD28 in complete DMEM medium at 37uC.
Culture supernatants were harvested 48 h later and the levels of
cytokines were determined via ELISA. To measure levels of
TNFa/IL10 in the culture medium, the OptEIA Set Mouse TNF/
IL10 kits from BD Biosciences were used according to manufac-
turer’s instructions. Briefly, the wells of a Nunc MaxiSorp 96-well
plate were coated overnight with the appropriate dilution of
capturing antibody in coating buffer (0.2 M sodium phosphate
buffer pH 6.5). The plate was washed three times with PBS-T
(PBS, 0.05% Tween-20) and blocked with Assay Diluent for 1 hr
at RT. After washing as before, 100 ml of sample or cytokines
standard prepared in assay diluent were added followed by 2 h
incubation at RT. After 5 washes with PBS-T, 100 ml of assay
diluent containing biotin-conjugated detection antibody and
Avidin-HRP reagent at the appropriate dilutions were added
and incubated for 1 h at RT. Following 7 washes with PBS-T
100 ml of Substrate Solution was added to each well. After 30 min
incubation in the dark, 50 ml of Stop Solution (2N H2SO4) were
added and absorbance at 450 nm was read within 30 min on a
SpectraMax microplate reader using the Softmax Pro software.
Mixed cortical and primary microglia cultures
Tissue culture plates used for plating mixed cortical cultures
were coated overnight at 4uC with 5 mg/ml poly-D-lysine (PDL,
Sigma). Newborn (d0–d2) pups of wild-type mice were used to
isolate cortical cells. The brains were removed, and cortices were
freed from meninges, hippocampi and basal ganglia and kept in
HBSS on ice. The cortical tissue was digested in 0.25% Trypsin/
EDTA (Sigma) at 37uC for 20 min. The tissue was then triturated
and filtered through a 40 mm cell strainer. The cell suspension was
plated in the mixed cortical medium (DMEM, 10% FBS, 40 mg/
ml Gentamycin).
The medium was changed 3 days after plating. Microglial cells
were harvested 10 days after plating. Briefly, lidocaine was added
directly to the culture medium at a final concentration of 1 mM
and the culture left at room temperature for 15 min. The medium
containing the floating microglia was collected and centrifuged at
500 g for 5 min, following which the cell pellet resuspended in
microglia medium (DMEM, 1% FBS) and counted on a
hemocytometer. The microglial cultures were .98% pure, as we
have previously described [29–32].
Primary Cortical Neuronal Cultures
Primary cortical neurons were cultured as previously described
[33,34]. Briefly, tissue culture plates were coated overnight at 4uC
with 5 mg/ml poly-D-lysine (PDL, Sigma). Primary neuronal
cultures were prepared from the cortices of embryonic day 14–15
pups. Briefly, mouse cortices were dissected and put in Hanks
solution (HBSS), and gently trypsinized (0.25% trypsin in HBSS)
at 37uC for 40 minutes and then triturated to form single cell
suspensions. The cells were plated at a density of 100,000 cells/
cm
2 in Neurobasal medium with B27 supplements, 25 mM
glutamate, 0.5 mM L-glutamine and 10 g/L gentamycin sulfate.
AraC (10 mM) was added to the medium on day 2 of the culture to
inhibit the growth of astrocytes. The neuronal cultures were
.95% pure.
PCR arrays
Mouse inflammatory cytokines and receptors arrays (SA-
Bioscience) were used on RNA samples isolated from T cells.
Briefly, RNA was isolated from T cells after different treatments.
cDNA was prepared from RNA samples using RT2 First Strand
Kit (SABioscience). cDNA and RT-PCR master mix were added
to 96-well PCR array plate. Thermal cycling was performed. Data
was analyzed using PCR Array Data Analysis Web Portal
provided by SABiosciences.
RNA isolation and quantitative real-time PCR
RNA was isolated from cells using RNA-Bee (Tel-Test), by the
manufacturer’s protocol. To obtain cDNA, the High Capacity
cDNA Reverse Transcription kit was used on a Veriti Thermo-
cycler (Applied Biosystems). Amplification was performed on a
StepOnePlus real-time PCR machine using a SYBR Green kit
(Applied Biosystems). Primer sequences are as follows: GAPDH
forward, 59-GCACAGTCAAGGCCGAGAAT-39; GAPDH re-
verse, 59-GCCTTCTCCATGGTGGTGGA-39; IL-10 forward,
59-TGGCCACACTTGAGAGCTGC-39; IL-10 reverse, 59-
TTCAGGGATGAAGCGGCTGG-39; TNFa forward, 59-AT-
GAGCACAGAAAGCATGATC-39; TNFa reverse, 59-TA-
CAGGCTTGTCACTCGAATT-39.
Proteomic analysis of conditioned media
Sample Preparation. Samples for proteomic analysis were
derived from serum- and supplement-free conditioned media, and
were concentrated in Amicon Ultra-15, UltraCel 3 k columns
(ThermoFisher) to acquire appropriate concentrations for
digestion. Protein concentration was determined by the EZQ
protein quantification assay (Invitrogen, CA) according to the
manufacture suggested protocol.
Trypsin Digestion. 50 mg of proteins from the conditioned
media were diluted in 50 mM NH4HCO3 solution for trypsin
digestion. Trypsin was added to each sample at a ratio of 1:30
enzyme/protein along with 2 mM CaCl2 and incubated for
16 hours at 37uC. Following digestion, all reactions were acidified
with 90% formic acid (2% final) to stop proteolysis. Then, samples
were centrifuged for 30 minutes at 14,000 rpm to remove
insoluble material. The soluble peptide mixtures were collected
for LC-MS/MS analysis.
Multidimensional chromatography and tandem mass
spectrometry. Peptide mixtures were pressure-loaded onto a
250 mm inner diameter (i.d.) fused-silica capillary packed first with
3c mo f5mm strong cation exchange material (Partisphere SCX,
Whatman), followed by 3 cm of 10 mm C18 reverse phase (RP)
particles (Aqua, Phenomenex, CA). Loaded and washed
microcapillaries were connected via a2 mm filtered union
(UpChurch Scientific) to a 100 mm i.d. column, which had been
pulled to a 5 mm i.d. tip using a P-2000 CO2 laser puller (Sutter
Instruments), then packed with 13 cm of 3 mm C18 reverse phase
(RP) particles (Aqua, Phenomenex, CA) and equilibrated in 5%
acetonitrile, 0.1% formic acid (Buffer A). This split-column was
then installed in-line with a NanoLC Eskigent HPLC pump. The
flow rate of channel 2 was set at 300 nl/min for the organic
gradient. The flow rate of channel 1 was set to 0.5 ml/min for the
salt pulse. Fully automated 11-step chromatography runs were
carried out. Three different elution buffers were used: 5%
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formic acid (Buffer B); and 0.5 M ammonium acetate, 5%
acetonitrile, 0.1% formic acid (Buffer C). In such sequences of
chromatographic events, peptides are sequentially eluted from the
SCX resin to the RP resin by increasing salt steps (increase in
Buffer C concentration), followed by organic gradients (increase in
Buffer B concentration). The last chromatography step consists in
a high salt wash with 100% Buffer C followed by acetonitrile
gradient. The application of a 2.5 kV distal voltage electrosprayed
the eluting peptides directly into a LTQ-Orbitrap XL mass
spectrometer equipped with a nano-LC electrospray ionization
source (ThermoFinnigan). Full MS spectra were recorded on the
peptides over a 400 to 2000 m/z range by the Orbitrap, followed
by five tandem mass (MS/MS) events sequentially generated by
LTQ in a data-dependent manner on the first, second, third, and
fourth most intense ions selected from the full MS spectrum (at
35% collision energy). Mass spectrometer scan functions and
HPLC solvent gradients were controlled by the Xcalibur data
system (ThermoFinnigan, San Jose, CA).
Database search and interpretation of MS/MS
datasets. Tandem mass spectra were extracted from raw files,
and a binary classifier - previously trained on a manually validated
data set - was used to remove the low quality MS/MS spectra. The
remaining spectra were searched against a UniProt mouse protein
database released on May, 3
rd 2011 [35] and 124 common
contaminant proteins. To calculate confidence levels and false
positive rates, we used a decoy database containing the reverse
sequences of the UniProt protein database appended to the target
database [36], and the SEQUEST algorithm to find the best
matching sequences from the combined database. SEQUEST
searches were done through the Integrated Proteomics Pipeline
(IP2, Integrated Proteomics Inc., CA) on Intel Xeon X5450 X/3.0
PROC processor clusters running under the Linux operating
system. The peptide mass search tolerance was set to 50 ppm. No
differential modifications were considered. A fully tryptic status
was imposed on the database search.
The validity of peptide/spectrum matches was assessed in
DTASelect2 [37] using SEQUEST-defined parameters, the cross-
correlation score (XCorr) and normalized difference in cross-
correlation scores (DeltaCN). The search results were grouped by
charge state (+1, +2, and +3) and tryptic status (fully tryptic, half-
tryptic, and non-tryptic), resulting in 9 distinct sub-groups. In each
one of the sub-groups, the distribution of XCorr and DeltaCN
values for (a) direct and (b) decoy database hits was obtained, and
the two subsets were separated by quadratic discriminant analysis.
Outlier points in the two distributions (for example, matches with
very low Xcorr but very high DeltaCN were discarded. Full
separation of the direct and decoy subsets is not generally possible;
therefore, the discriminant score was set such that a false discovery
rate of 1% was determined based on the number of accepted
decoy database peptides. This procedure was independently
performed on each data subset, resulting in a false positive rate
independent of tryptic status or charge state. In addition, a
minimum sequence length of 7 amino acid residues was required,
and each protein on the final list was supported by at least two
independent peptide identifications unless specified. These addi-
tional requirements – especially the latter - resulted in the
elimination of most decoy database and false positive hits, as these
tended to be overwhelmingly present as proteins identified by
single peptide matches. After this last filtering step, the false
discovery rate was reduced to below 1%. Relative fold difference
between samples was derived using the spectral counting method
[38,39].
Figure 1. Cytokine production from direct or indirect exposure
of T cells to tuftsin. (A) ELISA assays were performed to quantitate
the proinflammatory cytokine TNFa and the anti-inflammatory cytokine
IL10 as produced by splenic T cells exposed directly to varied
concentrations of tuftsin, as described in Methods. n=4, *, p,0.5; **,
p,0.01; ***, p,0.001. When ELISA assays were performed to quantitate
pro-inflammatory cytokine TNFa (B) and anti-inflammatory cytokine
IL10 (C) production by T cells after treatment with microglial-
conditioned medium (MgCM). The microglia were challenged either
with tuftsin or with tuftsin and conditioned medium from neurons
(NCM) that had been exposed to glutamate. n=4, *, p,0.5; **, p,0.01;
***, p,0.001.
doi:10.1371/journal.pone.0034933.g001
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changes in gene expression of the M1 marker TNFa (A) and the M2 marker IL10 (B) in response to tuftsin and NCM treatment for 10 hours. Primary
microglia were treated with increasing concentrations of tuftsin or tuftsin and NCM prepared from primary cortical neurons exposed to 100 mM
glutamate overnight. (C) The ratio of the fold change of IL10 (M2) to the fold change of TNFa (M1). n=3, *, p,0.5; **, p,0.01; ***, p,0.001. In (A) and
(B) the comparisons are between tuftsin and tuftsin/NCM at each concentration. In (C) the comparisons are between NCM and tuftsin/NCM.
doi:10.1371/journal.pone.0034933.g002
Table 1. Treatment of microglia with NCM and tuftsin induced the release of immunomodulatory factors.
Description Levels in MgCM Levels in MgCM+tuf MgCM+tuf/MgCM
Uncharacterized protein Igf1 1 8 8
Uncharacterized protein TnfaIp8 1 8 8
Phospholipase D3 2 10 5
Glia maturation factor Gmfb 2 9 4.5
Mannosidase alpha 1C 1 4 4
Procathepsin H 6 22 3.7
Monocyte differentiation antigen CD14 8 26 3.3
Macrophage scavenger receptor 1 3 3
Neuropilin2 1 3 3
Neuropilin1 10 13 1.3
Disintegrin and metalloproteinase domain-containing
protein 10, Adam10
04 .4
To characterize the factors released from microglia under EAE-like conditions, microglia were treated for 10 hours with NCM isolated from neurons undergoing
excitotoxic injury in the presence or absence of tuftsin. Concentrated conditioned media were analyzed by multidimensional chromatography and tandem mass
spectrometry. Partial list of the secreted proteins is shown. Spectral counts (MS/MS) of proteins identified from the media of microglia treated with NCM alone (MgCM)
or a combination of NCM and 100 mg/ml of tuftsin (MgCM+Tuf) for 10 hours are listed in the respected columns. Ratios derived from spectral counts were used to
predict the trend of differential expression.
doi:10.1371/journal.pone.0034933.t001
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Statistical analysis was performed using one-way ANOVA
followed by a Bonferroni-Dunn test for multiple comparisons
within a group, or a two-tailed t-test for comparisons between
groups as indicated in the figure legends; p,0.05 was considered
significant and is marked by an (*); p,0.01 and p,0.001 were
considered very significant and are marked by two (**); and three
(***) respectively. All results are represented as average with error
bars indicating the standard error of the mean. In all experiments,
n refers to the number of animals used for each genotype or
condition.
Results
Excitotoxic- and tuftsin-activated microglia shift the T cell
phenotype towards immunosuppression in culture
We previously reported that tuftsin-infused mice exhibit an
immune response that is shifted towards an anti-inflammatory
phenotype [21]. We proposed that the immediate effect of tuftsin
acceleration of microglial activation was to alter the relative
abundance of T cell subsets (the T cell ‘‘phenotype’’). However, it
was also possible that tuftsin might exert a direct effect on T cells
in this setting. We investigated these hypotheses using primary cell
cultures.
To test whether tuftsin has a direct effect on T cells, we isolated
primary splenic T cells as described in Methods. A range of
concentrations of tuftsin was added to individual cultures. 3 days
later, supernatants from the T cell cultures were collected, and
ELISA assays performed to quantitate the production of the Th1
cytokine tumor necrosis factor (TNFa) and the Th2 cytokine
interleukin 10 (IL10). TNFa levels increased up to 6-fold (Fig. 1A),
consistent with prior reports of T cells having a tuftsin receptor
and producing TNFalpha in response to tuftsin stimulation [18],
but there was no effect on production of IL10. Given that TNFa is
a proinflammatory cytokine, these findings would not explain our
prior results that tuftsin treatment in vivo decreases the levels of
proinflammatory transcription factors and increases the levels of
anti-inflammatory ones.
To examine the potential indirect effect of tuftsin on T cells, we
designed culture conditions to mimic the effects of in vivo tuftsin
infusion in the EAE model. As it has been previously described
that early excitotoxic injury plays a crucial role in EAE [40,41], we
simulated this in culture by treating primary neurons overnight with
100 mM glutamate to generate neuronal-conditioned medium
(NCM). Primary microglia were then incubated with the NCM
and tuftsin for 10 hours to generate the NCM-treated microglial-
conditioned medium, which was collected and added to primed T
cells. 3 days later, supernatants from the T cell cultures were
collected and analyzed as above. Microglial-conditioned medium
prepared from microglia stimulated only with NCM (NCM curve,
0 mg/ml concentration point) had no effect on cytokine secretion
by the T cells (Fig. 1B,C) in comparison to medium prepared from
non-stimulated microglia (tuftsin curve, 0 mg/ml concentration
point). Microglial-conditioned medium prepared from microglia
stimulated only with tuftsin also resulted in unchanged cytokine
secretion by the T cells. However, since tuftsin had a direct effect
on T cells to stimulate TNFalpha production (Fig. 1A), it would
appear that tuftsin-stimulated microglia do secrete factors that
counter the pro-inflammatory T cell response to tuftsin. More
dramatically, the combination of NCM and tuftsin stimulation of
microglia yielded a microglial-conditioned medium that had a
profound effect on the TNFa and IL10 levels recorded. TNFa
release decreased 4-fold in a tuftsin dose-dependent manner,
whereas IL10 release increased nearly 10-fold, resulting in a .35-
fold shift towards immunoprotection. Taken together, these in
culture experiments suggested that modulating microglial activity
with tuftsin under glutamate-stimulatory conditions affects the T
cell phenotype by down-regulating inflammatory Th1 responses
while up-regulating cytokines known to have immunosupressive
effects consistent with a Th2 phenotype.
Tuftsin-activated microglia exposed to excitotoxic media
polarize to an anti-inflammatory, M2 phenotype
As microglial involvement is necessary for mediating tuftsin’s
beneficial effects in culture, we next analyzed the changes that occur
in the treated microglia. Similar to T cells, microglia have pro- and
anti-inflammatory subsets known as M1 and M2. M1 microglia,
which are neurodegenerative in a model of spinal cord injury,
produce TNFa and nitric oxide, while neuroprotective M2
microglia release IL10 and TGFb [42–44]. Additionally, admin-
istration of M2 monocytes in EAE suppressed ongoing severe
symptoms [45]. We proposed that the combination of tuftsin and
NCM would cause microglia to shift to an anti-inflammatory, M2
phenotype, which could explain the prevalence of Th2 cytokines
in the previous figure.
To observe the effect of tuftsin and NCM on the microglial
subtype, we treated primary microglia for 10 hours with NCM
and increasing concentrations of tuftsin as above. From these cells
we harvested RNA and performed quantitative real-time PCR to
determine microglial phenotype based on TNFa levels for M1,
and IL10 levels for M2. The combination of NCM and tuftsin at
all concentrations significantly affected M1 and M2 specific genes
in the microglia, with a 3-fold increase in IL10 and a 3-fold
decrease in TNFa (Fig. 2A,B). More dramatically, when observing
the ratio of the change in M2 to M1 genes, there is greater than a
10-fold shift towards neuroprotection (Fig. 2C). Surprisingly,
Table 2. PCR array results indicating changes in mRNA levels of T cells after tuftsin treatment.
Fold Change in mRNA levels of anti-inflammatory cytokines and receptors (compared to control group)
Gene Symbol Group 1 (NCM) Group 2 (Tuftsin) Group 3 (Tuftsin+NCM)
Tumor necrosis factor (TNF)a 1.38 1.0 0.12
TNF receptor 1a (TNFRSF1a) 0.77 0.75 0.12
TNFRSF1b 1.27 0.96 0.09
Bcl6 0.89 0.86 0.20
T cells were treated with MgCM that was isolated from microglia treated with NCM alone, 100 mg/ml of tuftsin alone, or a combination of NCM+100 mg/ml tuftsin for
10 hours. After 3 days, mRNA was isolated from T cells and was reverse-transcribed and used to probe a PCR array kit of inflammatory cytokines and their receptors to
determine the subtype of T cells present as a result of treatment, as described in Methods. n=2.
doi:10.1371/journal.pone.0034933.t002
Anti-Inflammatory Neuroprotective Tuftsin in EAE
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34933NCM alone shows a slight shift towards neuroprotection, with a
decrease in TNFa and an increase in IL10 gene expression.
However, the combination of tuftsin and NCM shows a
significantly higher upregulation of IL10 than NCM alone, and
the degree of neuroprotection represented by the M2/M1 ratio for
NCM alone is significantly less than the combination of NCM and
tuftsin. Additionally, it has been shown that moderate neuronal
cell death can cause microglia to assume a more protective
phenotype, which could explain this phenomenon [46]. Thus,
these experiments indicate that the combination of NCM and
tuftsin promotes an anti-inflammatory, M2 phenotype in microg-
lia, which is the likely cause for the polarization of T cells towards
a Th2 phenotype as shown above.
Microglia shed factors in response to tuftsin
treatment. To determine what components present in the
microglial conditioned medium could act on T cells, we repeated
the experiment described in Fig. 1 and 2, collected and
concentrated media from treated microglia. The control
microglial conditioned media, which was derived from microglia
exposed to NCM alone (MgCM), and samples obtained from
microglia treated with NCM and tuftsin (MgCM+tuftsin) were
concentrated and digested with trypsin and subjected to shotgun
proteomic analysis. Several proteins were identified whose
expression was upregulated with tuftsin treatment, a short list of
which is shown (Table 1). The presence of some of these factors
(e.g., PLD3, Nrp1) were confirmed by western blot analysis (Figure
S1). Most interestingly, Nrp1, tuftsin’s receptor [47], was
upregulated in the MgCM+Tuf treatment. The presence of this
factor in the analyzed conditioned media, despite its role as a cell
surface receptor, is likely due to its shedding from the cell surface
by the protease ADAM10 [48], which was also present in the
analyzed conditioned media.
The T cell shift towards immunosupression after
exposure to excitotoxic- and tuftsin-activated microglial
conditioned medium takes place on a transcriptional
level
We extended these observations by performing RT-PCR on
mRNA from T cells cultured in differing types of conditioned
medium, using an array of primers to analyze a panel of cytokines
and their receptors. Reinforcing the findings shown in Fig. 1B,C,
the mRNA expression level of TNFa was decreased 9-fold, and
that of IL10 increased 23-fold, when T cells were cultured in
conditioned medium prepared from microglia stimulated by both
NCM and tuftsin (Tables 2 and 3). This result links the changes in
cytokine secretion to the altered levels of inflammation- and
immunosuppression-promoting transcription factors that we had
reported previously [21].
Expanding the response pattern, the mRNA levels of TNFalpha
receptors 1a and 1b also decreased after treatment with NCM plus
tuftsin-conditioned microglial medium, as was the case for Bcl6,
Table 3. PCR array results indicating changes in mRNA levels of T cells after tuftsin treatment.
Fold Change in mRNA levels of pro-inflammatory cytokines and receptors (compared to control group)
Gene Symbol Group 1 (NCM) Group 2 (Tuftsin) Group 3 (Tuftsin+NCM)
Interleukin 10 (IL10) 2.54 1.03 23.42
IL10 receptor (IL10Ra) 0.84 0.70 19.42
IL10Rb 1.09 1.19 6.59
IL13 1.06 0.77 12.73
IL4 1.67 0.79 15.12
Transforming growth factor (TGF) beta 1 1.30 1.24 27.61
Chemokine receptor (CCR)3 0.97 0.84 36.83
CCR5 0.93 31.09 86.96
Interferon (IFN) gamma 1.19 0.84 7.61
T cells were treated with MgCM that was isolated from microglia treated with NCM alone, 100 mg/ml of tuftsin alone, or a combination of NCM+100 mg/ml tuftsin for
10 hours. After 3 days, mRNA was isolated from T cells and was reverse-transcribed and used to probe a PCR array kit of inflammatory cytokines and their receptors to
determine the subtype of T cells present as a result of treatment, as described in Methods. n=2.
doi:10.1371/journal.pone.0034933.t003
Figure 3. Tuftsin infusion induces the expression of Th2 and
Treg cell markers. Western blot analyses were performed on mouse
spinal cord extracts at different timepoints following EAE induction to
examine protein expression in the presence or absence of 500 mM
tuftsin infusion. (A) Phosphorylation of STAT1 and the levels of the anti-
inflammatory cytokines IL10 and IL4 were assessed in extracts from
tuftsin-infused wt mice subjected to EAE. Equal loading of protein was
confirmed by pan-STAT1 blotting. (B) Levels of the Treg transcription
factor FoxP3 and the Treg cell surface marker CD25. Equal loading of
protein was confirmed by actin blotting. (Western blots were repeated
three times on mouse spinal cord samples from three separate EAE
experiments, n=3).
doi:10.1371/journal.pone.0034933.g003
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Conversely, the levels of expression of the alpha and beta
receptors for IL10 increased, as did those for several other anti-
inflammatory cytokines such as Interleukin 13 (IL13), Interleukin 4
(IL4), and Transforming Growth Factor b1 (TGFb1), which
stimulates the development of immunosuppressive regulatory T
cells [50]. Similarly, CCR3, a chemokine receptor that mediates
recruitment of Th2 cells [51], was upregulated.
CCR5, a chemokine receptor expressed primarily by Th1 cells
[52], was the only gene that responded significantly to medium
conditioned only with tuftsin, suggesting that it potentially ensues
from direct T cell or microglial stimulation by tuftsin rather than
by factors produced by the microglia in the context of
excitotoxicity. Finally, modest upregulation was also observed for
interferon c (IFNc), which has been reported to function in both
pro- and anti-inflammatory contexts in EAE, as IFN-c knockout
mice exhibit increased susceptibility to EAE [53]. Taken together,
the PCR array results revealed that modulating microglia activity
with NCM and tuftsin efficiently down-regulates Th1-type
responses, upregulates Th2-type responses, and releases factors
that promote immunosuppressive regulatory T cell formation.
The transcriptional changes observed in T cells exposed
to excitotoxic- and tuftsin-activated microglial
conditioned medium are mediated by suppression of
STAT1-signaling and stabilization of the FoxP3
transcription factor
We next assessed regulatory pathways potentially involved in
the transcriptional changes seen in Tables 2 and 3. STAT1 is a
member of the Signal Transducers and Activators of Transcription
family of transcription factors that upregulates pro-inflammatory
cytokines (TNFa and IL12) while repressing production of anti-
inflammatory cytokines (IL10). STAT1 phosphorylation (activa-
tion) has been shown to be increased in EAE lesions [54]. In
contrast, FoxP3, a regulatory T cell transcription factor, facilitates
the commitment towards regulatory T cell lineage by amplifying
and stabilizing its own expression and repressing alternative cell
fates in response to the immunosuppressive cytokine TGFb, which
suppresses STAT1 signaling [50] and upregulates the transmem-
brane surface protein CD25. We evaluated the levels of STAT1
phosphorylation, FoxP3, CD25, and immunosuppressive cytokine
expression in spinal cord homogenates prepared from mice
subjected to MOG-induced EAE with and without administration
of tuftsin. As shown in Fig. 3, phospho-STAT1 expression
increased on days 21 and 30 in MOG-immunized PBS-infused
control mice, and levels of the immunosuppressive cytokines IL4
and IL10, FoxP3, and the Treg marker CD25 remained low or
undetectable. However, administration of tuftsin strongly blunted
the increase in phospho-STAT1 while increasing synthesis of
IL10, IL4, FoxP3, and CD25. Thus, tuftsin administration shifts
the balance of the immune response from pro-inflammation
(phospho-STAT1) to anti-inflammation (IL4 and IL10) and
immunosuppression (FoxP3, CD25). Taken together, these results
suggest that in vivo, tuftsin infusion promotes downregulation of
Th1 signaling, increased activity of Th2 cells, and expansion of
Treg cells.
T cells stimulated by excitotoxic- and tuftsin-activated
microglial conditioned medium reverse clinical
symptoms following adoptive transfer into mice with
established EAE
To assess whether the protective effect of tuftsin in EAE is
mediated by indirect modulation of the balance and activity of T
cell subsets, we transferred T cells cultured in excitotoxic- and
Figure 4. Adoptive transfer of tuftsin and NCM modulated T cells on day 14 ameliorates established EAE. Wild-type (WT) mice were
injected with MOG35–55 peptide in CFA and pertussis toxin to induce EAE. Osmotic pumps filled with PBS or 500 mM tuftsin in PBS were implanted in
the back of the mice on day 1 after MOG immunization. 5610
6 T cells, modulated as follows: tuftsin/NCM-treated T cells; tuftsin-only treated T cells;
NCM-only treated T cells, were injected intravenously into recipient C57BL/6 mice immunized with MOG 14 days after the onset of disease (arrow
indicates timepoint when T cell transfer was performed) and the disease severity scored as described in Methods. (The experiment was repeated
twice. Cumulative data are provided; total number of animals tested, n=12/PBS-infused mice; n=12/tuftsin-infused mice; n=12/mice adoptively
transferred with tuftsin plus NCM-modulated T cells; n=5/mice adoptively transferred with tuftsin-only treated T cells; n=5/mice adoptively
transferred with NCM-only treated T cells). Statistical analysis was performed, as described in the Methods. All time points between tuftsin/NCM-
treated T cells and PBS control were found to be significant (p,0.001) except for days 14–15, 34 and 41–44). All the timepoints between tuftsin alone
and PBS were significant (p,0.001). No difference was evident between tuftsin and tuftsin/NCM-treated T cells.
doi:10.1371/journal.pone.0034933.g004
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had been subjected to MOG immunization to generate EAE.
5610
6 T cells cultured in excitotoxic- and tuftsin-activated
microglial conditioned medium as described above were injected
intravenously 14 days after the onset of disease into recipient
C57BL/6 mice immunized with MOG. The treatment was
initiated on day 14 to assess whether existing EAE could be
modified. T cells treated with NCM/tuftsin-modulated microglial
medium decreased the clinical signs of EAE, and the disease
course paralleled that of tuftsin-infused animals (Fig. 4). In
contrast, T cells treated with NCM-only or tuftsin-only stimulated
microglial conditioned medium were unable to alter the clinical
course of EAE in comparison to that of PBS-infused control mice.
The results suggest that the shift towards immunosuppression
observed for T cells after culture in excitotoxic- and tuftsin-
activated microglial conditioned medium is functional in vivo and
just as potent as directly administering tuftsin to the EAE-afflicted
mice. Taken together, this suggests that the mechanism of tuftsin’s
suppression of EAE in vivo is via promotion of a shift in the T cell
phenotype consistent with suppression of the immune response.
EAE mice adoptively transferred with T cells stimulated
by excitotoxic- and tuftsin-activated microglial
conditioned medium have attenuated demyelination
The histological hallmark of EAE consists of demyelination,
which can be assessed using Eriochrome Cyanine (EC) staining.
The timing of spinal cord demyelination is well established to
correlate closely with clinical progression in this disease model.
MOG-induced EAE was established in three groups of mice,
which were then individually infused with PBS, infused with
tuftsin, or adoptively transferred with T cells stimulated by
excitotoxic- and tuftsin-activated microglial conditioned medium
as above. None of the groups exhibited significant demyelination
on day 15 (Fig. 5A). By the peak of disease (day 22), however, the
PBS-infused EAE mice were remarkable for they showed severe
demyelination in the spinal cord white matter, as characterized by
large areas devoid of EC staining (arrows). In contrast, EAE mice
infused with tuftsin exhibited much less demyelination, and mice
adoptively transferred with the stimulated T cells were similarly
protected. At day 30, there were still apparent demyelinated areas
visible in the PBS-infused mice (arrows), but the two treated
groups had undergone almost complete remyelination.
Figure 5. Attenuated demyelination in EAE mice adoptively transferred with tuftsin/NCM-modulated T cells. (A) Frozen cross-sections
of spinal cords were isolated at different time points during the EAE from PBS-infused wild-type mice, Tuftsin-infused wild-type mice, and wild-type
mice adoptively transferred with Tuftsin/NCM-modulated T cells. Spinal cord sections were stained with Eriochrome cyanine (EC), which visualizes
myelin (blue). Sites of demyelination are indicated by arrows. (B) Use of FluoroMyelin to fluorescently and C. quantitatively image myelin.
Quantifications were performed on five sections per mouse for three different mice per timepoint in two separate EAE experiments; results are
presented as an average with error bars indicating the standard error of the mean. A two-tailed t test was performed to analyze the significance of
the difference of FluoroMyelin staining intensity across groups at each timepoint (*** p,0.001; **p,0.01).
doi:10.1371/journal.pone.0034933.g005
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fluorescent myelin stain, with which similar results were obtained
(Fig. 5B, arrows indicate sites of demyelination). Quantification of
the fluorescence intensities (Fig. 5C) revealed that the extent of
demyelination in the group of mice that received the adoptively
transferred T cells was comparable to that observed in the tuftsin-
infused mice group, and both showed significantly increased
myelination than the group of mice infused with PBS.
Figure 6. Reduced microglia/macrophage infiltration and activation in mice with adoptive transfer. (A) Frozen cross-sections of spinal
cords from PBS, tuftsin-infused and T-cell adoptively transferred mice at different time points in EAE were stained with anti-Iba1 to detect microglia/
macrophages. Iba1 is expressed on both resting and activated microglia/macrophages, which can be distinguished by their morphological
appearance. Arrows indicate resting microglia, characterized by long, thin cell bodies. Arrowheads indicate activated microglia/macrophages that are
characterized by thicker, rounded cell bodies and multi-branched cellular protrusions (The experiment was repeated three times. In total, five mice
per genotype were assessed for immunostaining at each timepoint; representative data are provided.) (B) Mouse spinal cord extracts were collected
at different timepoints after induction of EAE and analyzed using western blotting to quantify the levels of Iba1. Equal loading of protein was
confirmed by anti-actin blotting (the western blot was repeated three times on mouse spinal cord samples from two separate EAE experiments).
doi:10.1371/journal.pone.0034933.g006
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microglia/macrophage infiltration and activation in mice
subjected to EAE
During EAE, activated microglia signal to attract infiltrating T
cells which attack the endogenous myelin. Myelin degradation
products then recruit additional activated microglia to the
demyelinated areas to remove myelin and cellular debris using
their phagocytotic capacity [55,56]. We evaluated the levels of
microglia/macrophage activation and recruitment at different
time-points (Day 15, 22, 30) during EAE, using an antibody
against Iba1, which is expressed at low levels by resting microglia/
macrophages and becomes upregulated during their activation.
Iba1 staining on day 15 revealed resting microglia/macrophages
in all groups, as defined by the cells’ ramified morphology with
long thin cell bodies (arrows, Fig. 6A). On day 22, PBS-infused
mice exhibited large numbers of microglia/macrophages that had
undergone activation in the white matter of the spinal cord, as
indicated by their ameboid shape and extensive branches, and the
activated microglia/macrophages continued to be evident through
day 30. In contrast, in tuftsin-infused mice and in mice with
adoptively transferred T cells, there were also activated microglia
by day 22, but they were much less frequent than in the PBS-
infused mice. By day 30, the number of Iba1-positive cells had
decreased in the treated animals, with most of the microglia and
macrophages re-assuming a resting morphology.
Spinal cord extracts were assayed in parallel using western
blotting to quantitate Iba1 expression, as a semi-quantitative
measure of the extent of microglia/macrophage recruitment and
activation (Fig. 6B). All three groups expressed Iba1 at basal levels
on day 15, and the level of Iba1 increased as disease progressed.
PBS-infused animals showed a dramatic upregulation of Iba1
levels on day 22, and then decreased while still remaining elevated
by day 30. In contrast, tuftsin-infused mice and mice that received
NCM/tuftsin treated T cells exhibited blunted Iba1 upregulation
on day 22, and had returned to basal levels of expression of by day
30. These results correlate with the extent of microglia/
macrophage activation described in panel A and with the clinical
symptoms described in Fig. 4 and histological features shown in
Fig. 5.
Discussion
Tuftsin’s broad activities on phagocytotic cells, especially
microglia and macrophages, make the peptide a potential
candidate for immunotherapy. As evidence, tuftsin and its analogs
have been chemically synthesized and applied in a variety of
clinical studies [57]. As the normal tuftsin serum level is 250–
500 ng/ml and the LD50 dose of tuftsin is 2.4 mg/ml, a serum
level of 60 mg/ml is a suitable physiological concentration for
applying tuftsin in therapeutic studies. Here, we delivered tuftsin
through mini-osmotic pumps at a concentration of 500 mM, with
an infusion rate of 0.25 ml/hour. In theory, an infusion of tuftsin at
0.06 mg per hour will diffuse along the length of the spinal cord
and surrounding tissues, bringing it to a physiological concentra-
tion for the therapeutic effects without other untoward effects.
In our previous work, we reported that early activation of
microglia/macrophages by tuftsin abrogated clinical symptoms in
EAE mice, and this correlated with a switch towards increased
expression of a Th2 transcription factor. These findings led us to
explore the concept of protective autoimmunity. In MS/EAE, the
balance between the pro-inflammatory Th1 response and the anti-
inflammatory Th2 response, together with the beneficial effect of
the regulatory T cells, is thought to determine the outcome of MS/
EAE. Here, we have found that after tuftsin treatment, markers of
Th2 and Treg cells are upregulated, suggesting that there is
activation of Th2 cells and expansion of Tregs. Our current
studies confirmed the idea that early activation of microglia by
tuftsin results in a coordination of the immune response that favors
protective autoimmunity as opposed to autoimmune disease.
However, it is not only T cells that function as the mediators of
tuftsin’s effects, as microglia are equally responsible for promoting
disease progression or resolution. Microglia have been shown to
play an important role in the demyelination process, both through
the induction of the inflammatory cascade by releasing pro-
inflammatory cytokines [44], and through interactions with MBP.
In the CNS, tissue plasminogen activator recruits and activates
microglia, which then promote demyelination through contact
with MBP peptides in the myelin sheath [58,59]. On the other
hand, microglia have been shown to play important roles in the
remyelination process, both through phagocytosis of debris and
support of myelinating oligodendrocytes [60], as well as through
promotion of axonal regeneration [61]. From the data presented
here, it is likely that the dual roles of microglia in the myelination
process can also be explained by the presence of M1 and M2
microglial subsets; as we show tuftsin is capable of promoting the
M2 anti-inflammatory phenotype in EAE.
Many treatments for MS aim at repression of the immune
response. Some reagents work by inhibiting activation of microglia
and T cells and cause a downregulation of the production of
proinflammatory cytokines [62]. These treatments attenuate MS
symptoms through their ‘‘anti-inflammatory effects.’’ Tuftsin,
however, appears to affect MS/EAE symptoms in a different
manner, by shifting the immune response towards an anti-
inflammatory phenotype. Tuftsin appears to modulate T cell
behaviors by enhancing Th2 cytokines and expanding Tregs, not
by just inhibiting the Th1 response. Thus tuftsin exerts its effect
through a more broad-based ‘‘modulation of the immune system.’’
As we have shown above, microglial conditioned media treated
with NCM alone or tuftsin alone on T cells was not capable of
promoting the shift towards anti-inflammation as the combination
treatment does. These cells appear to need a ‘‘two-hit’’ treatment
to successfully convert to a protective phenotype. This finding may
explain why NCM alone can promote a slight anti-inflammatory
shift in microglial populations that is not recapitulated downstream
in T cells, for there could be some other factors in play that NCM
alone is incapable of upregulating. However, the nature of this
second signal induced by tuftsin treatment is currently unknown.
Our proteomic screen identified several factors shed in the media
in the presence of tuftsin. Some of these factors were common for
the activated microglial secretome [63], while others were unique
to the tuftsin treatment.
Despite its 30-year history, the mechanism of action of tuftsin
remain unknown. However, based on the broad range of action of
tuftsin in both the immune and nervous systems, it is expected that
the tuftsin receptor(s) should be common in both systems. Cultured
human aortic and umbilical vein endothelial cells were shown to
express tuftsin receptors and that the identity of the receptor is
neuropilin-1 [47]. Because neuropilin-1 plays critical roles in the
immune, vascular, and nervous systems and interacts with a
number of different ligands, cell surface receptors and adhesion
proteins [64–66], it is possible that some of the previously reported
effects of tuftsin are mediated through neuropilin-1, which could
function as the second signal of the ‘‘two-hit’’ treatment that is
necessary to promote a full shift towards neuroprotection.
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Figure S1 Microglial shed factors in conditioned media.
To confirm the results of the proteomic screen aiming to
determine what factors are released by stimulated microglia,
conditioned media from primary microglia treated with NCM
alone or a combination of NCM and 100 mg/ml tuftsin for
10 hours were concentrated and analyzed by western blot for the
abundance of PLD3 (A) or Nrp1 (B). This western blot experiment
was repeated three times on media isolated from three separate in
vitro experiments. PLD3 fold change: 5.37 (5-fold change
documented from the proteomic data), Nrp-1 fold change: 1.23
(1.3 in the proteomic data).
(TIF)
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